Table 1.
Formalin-fixed paraffin-embedded cases used for fluorescent immunohistochemistry
| Case | GDS | Sex | Age (years) | ABC | Neuropathological diagnosis |
|---|---|---|---|---|---|
| Cognitively normal control 1 | ≤2 | M | 63 | A1,B1,C0 | Atherosclerosis |
| Cognitively normal control 2 | ≤2 | F | 71 | A0,B1,C0 | Atherosclerosis |
| Cognitively normal control 3 | ≤2 | M | 65 | A1,B0,C0 | Arteriosclerosis |
| Cognitively normal control 4 | ≤2 | M | 69 | A0,B0,C0 | Normal |
| Cognitively normal control 5 | ≤2 | M | 60 | A0,B0,C0 | Atherosclerosis |
| Cognitively normal control 6 | 2 | F | 84 | A0,B1,C0 | Normal |
| Cognitively normal control 7 | 2 | M | 84 | A1,B2,C1 | ADRC |
| MCI 1 | 3 | F | 97 | A1,B2,C1 | ADRC |
| MCI 2 | 3 | M | 95 | A0,B1,C0 | Small vessel disease |
| MCI 3 | 3 | F | 88 | A2,B2,C2 | ADRC/small vessel disease |
| MCI 4 | 3 | F | 88 | A2,B2,C2 | ADRC/peripheral vascular disease |
| MCI 5 | 3 | M | 84 | A2,B2,C2 | Lacunar infarct |
| MCI 6 | 3 | M | 85 | A2,B2,C2 | CAA |
| MCI 7 | 3 | F | 90 | A0,B2,C0 | Infarcts/CAA |
| MCI 8 | 3 | F | 83 | A2,B2,C2 | ADRC/ischemic damage |
| AD 1 | ≥5 | F | 83 | A3,B3,C3 | AD |
| AD 2 | ≥5 | F | 80 | A3,B3,C3 | AD |
| AD 3 | ≥5 | F | 80 | A3,B3,C3 | AD |
| AD 4 | ≥5 | F | 100 | A3,B3,C3 | AD |
| AD 5 | ≥5 | M | 81 | A3,B3,C3 | AD |
| AD 6 | ≥5 | M | 84 | A3,B3,C3 | AD |
| AD 7 | ≥5 | M | 74 | A3,B3,C3 | AD |
| AD 8 | ≥5 | M | 79 | A3,B3,C3 | AD |
| AD 9 | ≥5 | F | 91 | A3,B3,C3 | AD |
| AD 10 | ≥5 | M | 69 | A3,B3,C3 | AD |
| AD 11 | ≥5 | M | 75 | A3,B3,C3 | AD |
| AD 12 | ≥5 | F | 88 | A3,B3,C3 | AD |
| AD 13 | ≥5 | M | 66 | A2,B2,C2 | AD/CAA |
ABC score and neuropathological diagnosis was determined as previously published [31] and reported by a board-certified neuropathologist
AD Alzheimer’s disease, ADRC Alzheimer’s disease-related changes, CAA cerebral amyloid angiopathy, F female, GDS Global Dementia Scale [30], M male, MCI mild cognitive impairment